– RADIAN’s Five-Year, $25 Million
Extension Will Increase Support for Local Organizations and Drive
Progress to Help Turn the Tide on HIV Across the Region –
– RADIAN Will Expand Geographic Focus
to Provide Key Populations and Communities Impacted by the Conflict
in Ukraine with HIV Prevention and Care Services –
Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS
Foundation (EJAF) today announced a five-year extension of the
RADIAN® partnership to help meet the needs of the most vulnerable
key populations in Eastern Europe and Central Asia (EECA) where the
HIV epidemic is growing. RADIAN will continue supporting the
initiatives of trusted, grassroots organizations who are working to
address HIV-related challenges in the region.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240718867405/en/
Anne Aslett (CEO, Elton John AIDS
Foundation) and Daniel O'Day (Chairman and CEO, Gilead Sciences)
visit RADIAN Model City in Kazakhstan. (Photo: Business Wire)
While HIV is declining globally, EECA is one of the few regions
in the world where the epidemic is getting worse, with new HIV
diagnoses and AIDS-related deaths increasing by 20% and 34%,
respectively, since 2010.1 Of the 2.1 million people in EECA living
with HIV, 41% are not aware of their HIV status and 50% are not on
treatment – way below global 95-95-95-95 targets.1
“We are committed to ensuring that the EECA region is not left
behind because ending the HIV epidemic means ending it for
everyone, everywhere,” said Daniel O’Day, Chairman and Chief
Executive Officer, Gilead Sciences. “During a recent visit to
Kazakhstan, I met with RADIAN-supported community leaders who
emphasized the importance of doubling down on our collaborative
efforts. Over the next five years, RADIAN 2.0 will continue to
address the structural drivers of the epidemic, strengthen HIV
health systems, and enhance the capacities of local organizations
for lasting impact.”
Since RADIAN was launched in 2019 it has had a significant
impact on the HIV response in the region, reaching more than
271,000 people with HIV services, providing over 114,000 HIV tests,
(re-) initiating over 26,500 people on antiretroviral therapy, and
training more than 14,000 frontline workers to reduce stigma and
discrimination.2 These efforts are having an impact on communities
most in need, however the situation in the region has escalated
dramatically in recent years with the conflict in Ukraine further
exacerbating the crisis.3 Anti-LGBTQ+ legislation, human rights
violations, stigma and discrimination are also hindering the HIV
response across the region.4
“At the Elton John AIDS Foundation, we have a long history of
supporting people living with or at risk of HIV across Eastern
Europe and Central Asia – a region too often overlooked in the
global HIV response. Because of insufficient access to HIV testing
and effective treatment, 384 people newly acquire HIV every day in
EECA and 120 people die of AIDS-related causes,” said Anne Aslett,
CEO of the Elton John AIDS Foundation.1 “We are incredibly proud of
our RADIAN partnership with Gilead Sciences, which is genuinely
helping to turn the tide on the HIV epidemic in the region. Over
the next few years, RADIAN will continue to help meet the needs of
people most affected by HIV in EECA through innovative, scalable
solutions and we are incredibly grateful to our resilient and
determined local partners who share our ambition of leaving nobody
behind.”
Over the next five years, RADIAN will extend its efforts to
support collaborative, community-based initiatives to help meet the
needs of the most vulnerable key populations across EECA, including
people who use drugs, men who have sex with men, sex workers and
Transgender people.
RADIAN will also expand its geographic reach to include
countries hosting refugees fleeing Ukraine, including Hungary,
Poland, Slovakia and Germany, where there is an acute need for
additional HIV services. Language barriers, social isolation and
internalized stigma are all greatly hindering the ability of
refugees living with or at risk of HIV to access the treatment and
care they urgently need.5 RADIAN’s geographic expansion will
provide more support to these vulnerable communities, improving
access to HIV services and supporting their mental and social
wellbeing.
RADIAN will continue to build on successes and learnings from
the first five years of the partnership to help close gaps in HIV
testing, prevention and care. Additionally, to support innovations
that increase the effectiveness of the HIV response in EECA, RADIAN
will introduce an innovation fund. The fund will accept creative
applications on a rolling basis to allow for flexibility of funding
opportunities as innovations emerge.
About RADIAN
RADIAN is a ground-breaking partnership between Gilead Sciences
and the Elton John AIDS Foundation that supports grassroots
organizations and partners in Eastern Europe and Central Asia
(EECA) to meaningfully address the HIV-related challenges in the
region. By supporting the delivery of community-based services and
health systems, and by addressing structural barriers impeding the
HIV response, RADIAN helps address the needs of key populations and
marginalized communities – including people who use drugs, men who
have sex with men, sex workers and Transgender people. RADIAN works
closely with local leaders and community partners – RADIAN
Changemakers and grantees – who are committed to creating change in
the region through on-the-ground initiatives tackling the unique
challenges of the HIV epidemic in EECA.
To learn more about how RADIAN is working to end HIV in EECA,
visit www.radianhiv.org.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis, COVID-19, and cancer. Gilead operates in more than
35 countries worldwide, with headquarters in Foster City,
California.
For 35 years, Gilead has been a leading innovator in the field
of HIV, driving advances in treatment, prevention and cure
research. Gilead researchers have developed 12 HIV medications,
including the first single-tablet regimen to treat HIV, the first
antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce
new HIV infections, and the first long-acting injectable HIV
treatment medication administered twice-yearly. Our advances in
medical research have helped to transform HIV into a treatable,
preventable, chronic condition for millions of people.
For more information on Gilead Sciences, please visit the
company’s website at www.gilead.com.
About Elton John AIDS
Foundation
The Elton John AIDS Foundation was established in 1992 and is
one of the leading independent AIDS organizations in the world. The
Foundation's mission is simple: an end to the AIDS epidemic. The
Elton John AIDS Foundation is committed to overcoming the stigma,
discrimination and neglect that keep us from ending AIDS. With the
mobilization of our network of generous supporters and partners, we
fund local experts across four continents to challenge
discrimination, prevent infections, and provide treatment as well
as influencing governments to end AIDS.
www.eltonjohnaidsfoundation.org
1 Data provided by UNAIDS (2024), https://www.unaids.org/en 2
Data provided by the Elton John AIDS Foundation – June 2024 3
Jonas, Kai J. et al. The war refugees from Ukraine: an HIV epidemic
is fleeing as well. AIDS 36(12):p 1745-1746, October 1, 2022. |
DOI: 10.1097/QAD.0000000000003271, last accessed June 2024 4
Schweitzer AM et al, Addressing HIV stigma in healthcare,
community, and legislative settings in Central and Eastern Europe,
2023. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10714556/, last accessed June 2024 5 European Centre for
Disease Prevention and Control, Migrant health: HIV testing and
counselling in migrant populations and ethnic minorities in
EU/EEA/EFTA Member States. Available at:
https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/1108_TER_HIV_in_migrants.pdf,
last accessed July 2024.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240718867405/en/
Meaghan Smith, Media public_affairs@gilead.com
Jacquie Ross, Investors investor_relations@gilead.com
Gilead Sciences (NASDAQ:GILD)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Gilead Sciences (NASDAQ:GILD)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
